Dataset Information


The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC).

ABSTRACT: Significant progression has been achieved in the treatment of metastatic colorectal cancer (mCRC) in recent years. This has been partly attributed to successfully incorporating new drugs into combination chemotherapy. In addition to the traditional cytotoxic chemotherapeutic agents, molecularly targeted agents began to play an important role in the treatment of advanced solid tumors. To date, two classes of molecularly targeted agents have been approved for treatment of patients with mCRC: (1) antivascular endothelial growth factor (anti-VEGF) agents (such as bevacizumab and aflibercept) and (2) antiendothelial cell growth factor receptor (anti-EGFR) agents (such as cetuximab and panitumumab). Aflibercept is a new member of anti-VEGF agents which has demonstrated efficacy for treatment of mCRC. With the commencement of clinical trials and basic research into aflibercept, more data from the bedside and the bench have been obtained. This review will outline the application of anti-VEGF agents by reviewing clinic experiences of bevacizumab and aflibercept, and try to add perspectives on the use of anti-VEGF agents in mCRC.

PROVIDER: S-EPMC3345882 | BioStudies | 2012-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC3685399 | BioStudies
2020-01-01 | S-EPMC7281759 | BioStudies
2017-01-01 | S-EPMC5642319 | BioStudies
2020-01-01 | S-EPMC7066709 | BioStudies
2018-01-01 | S-EPMC6124467 | BioStudies
2014-01-01 | S-EPMC4221380 | BioStudies
2017-01-01 | S-EPMC5519808 | BioStudies
2018-01-01 | S-EPMC6568257 | BioStudies
| S-EPMC4930479 | BioStudies
2019-01-01 | S-EPMC6426764 | BioStudies